IHS Chemical Week

Regions :: Middle East

Lonza Signs Manufacturing Deal with Immune Pharmaceuticals

12:07 AM MDT | July 19, 2011 | Deepti Ramesh

Lonza says it has signed an exclusive contract for the production of Immune Pharmaceuticals’ (Tel Aviv, Israel) human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility, under the terms of the deal. Immune is a biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing unmet medical needs in the treatment of cancer and...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa